http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
William John Yaxley,Rhiannon McBean,David Wong,David Grimes,Paul Vasey,Mark Frydenberg,John William Yaxley 대한비뇨의학회 2021 Investigative and Clinical Urology Vol.62 No.6
Purpose: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of men with only lymph node metastasis (LNM) is unknown. The aim was to assess the outcome of Lu-PSMA RLT earlier in the treatment of men with only LNM. Materials and Methods: Single institution retrospective review of men with only LNM on staging Ga-PSMA PET PSMA who proceeded with Lu-PSMA RLT. Results: There were 17 men with only LNM, including 13 with mCRPC and 3 who were both hormone and chemotherapy naïve. The median PSA was 3.7 (0.46–120 ng/mL). A PSA decline of ≥50% occurred in 10/17 (58.8%), decreasing to <0.2 ng/mL in 35.3% (6/17). The PSA continues to decline or remain stable in 10/17 (58.8%) with a median follow-up of 13 months, and 8/17 (47.1%) have not reached their pre-treatment levels. There were no significant side effects. There was a better PSA response in men without prior chemotherapy (p=0.05). The prostate cancer specific and overall survival is 82.4% (14/17). Conclusions: Our results identify improved PSA response to Lu-PSMA RLT in men with only LNM, especially in the chemotherapy naïve cohort, compared to previous series with more advanced mCRPC. These findings provide important proof of principle to aid with planning of future prospective randomized trials evaluating the role of Lu-PSMA RLT earlier in the management of node metastatic prostate cancer, including men naïve of ADT and chemotherapy.
김창균,William Paul Clarke,David Lockington 한국지하수토양환경학회 1999 지하수토양환경 Vol.4 No.2
The unknown amount of thiolane retained on different soil matrix was characterized by employing an uniquely designed glass vessel, which was forced to purge the prepared slurry sample so that thiolane may diffuse into Tenax/charcoal tube. Thiolane can be recovered ranging from approximately 89% at 1 ppm regardless of soil types, which was not consequently affected by potential biodegradation during sample preparation. For 5ppm, thiolane is more recoverable up to 92% for sand, whereas it was poorly recovered as low as 85% for clay. It strongly suggests that controls should be considered when soil types varied in a concerned area. The technique was eventually capable of determination of thiolane for the samples taken from the site which led to be taken into consideration for proper site remediation.
Failure Demand: An evaluation of concept in UK Primary Care
( Paul Walley(dr) ),( Sharon Williams(dr) ),( Pauline Found(dr) ) 한국품질경영학회 2015 한국품질경영학회 학술대회 Vol.2015 No.2
Purpose - The purpose of this paper is to assess the characterisation of failure demand as service lean concept that assists in the analysis of waste during quality improvement activity. We assess whether the limited use of this concept is a missed opportunity to help understand improvement priorities given that a UK Government requirement for public services to report failure demand has been removed. Design/methodology/approach - The study looks at the existing literature across the public sector and then applies the concept of failure demand to the UK□s primary healthcare system. UK NHS demand data are analysed and the impact on patient care is elicited from patient interviews. Findings - The study highlighted the value of the concept, showing how the primary care system often generates failure demand partly because of existing demand and capacity management practices. This demand is deflected to other parts of the system with a considerable detrimental impact on the patient□s experience. Research implications - More research is now needed to fully understand how best to exploit the idea of failure demand as there are many barriers to its appropriate and successful application. Practical implications - The paper highlights three practical barriers: the lack of general understanding of demand within the healthcare system, the lack of understanding of systems improvement and the need to apply the concept for improvement not reporting purposes. Originality/value - The paper provides an objective and independent insight into the concept of failure demand that has not previously been seen in the academic literature.
Dupilumab Efficacy in Patients with GINA-Defined Type 2 Asthma: TRAVERSE
( William W. Busse ),( Eric D. Bateman ),( Ian D. Pavord ),( Nadia Daizadeh ),( Yamo Deniz ),( Paul J. Rowe ),( Juby A. Jacob-nara ),( Rebecca Gall ),( Nami Pandit-abid ),( Benjamin Ortiz ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Background The Global Initiative for Asthma (GINA) 2020 report recommends add-on biologics for patients with type 2 asthma (≥150 blood eosinophils/μL or FeNO ≥20ppb, largely allergen-driven disease). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/13, key and central drivers of type 2 inflammation. In QUEST (NCT02414854), add-on dupilumab 200/300mg every 2 weeks vs placebo reduced exacerbations and improved forced expiratory volume in 1 second (FEV1) in patients with uncontrolled, moderate-to-severe asthma. TRAVERSE, a single-arm, open-label extension study (NCT02134028), evaluated the long-term safety and efficacy of dupilumab in patients from QUEST. The objective was to assess the long-term efficacy of dupilumab in patients according to baseline type 2 biomarkers and allergic status as suggested by GINA. Methods Patients who received dupilumab or placebo in QUEST received dupilumab 300mg in TRAVERSE for up to 96 weeks. We evaluated annualized severe exacerbation rate (AER) and pre-BD FEV1 in type 2 patients with/without evidence of allergic asthma phenotype (serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L at parent study baseline). Results Dupilumab reduced AERs and improved pre-BD FEV1 in patients with elevated eosinophils or FeNO. These effects were sustained throughout TRAVERSE (Table). Allergic phenotype did not influence the efficacy of dupilumab. Conclusions Dupilumab reduced severe exacerbations and improved FEV1 for up to 96 weeks in patients with type 2 inflammatory asthma as specified in recent GINA recommendations, irrespective of allergic phenotype.